Spritam: A Comprehensive Guide on Uses, Dosage, Demographic, Side Effects, Interactions, and Generic Options Spritam is a medication used in the treatment of seizures or epilepsy. It contains the active ingredient levetiracetam, which is an antiepileptic drug that works by reducing abnormal electrical activity in the brain. As a high-tech medicine, it is the first FDA-approved 3D-printed prescription drug designed to dissolve in the mouth with a sip of liquid and is ideal for those who have difficulty swallowing tablets or capsules. Uses: Spritam is used as a primary treatment for partial onset seizures in adults and children with epilepsy. It can also be utilized as an alternative to other medications when those medications are not stopping seizures effectively. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial-onset seizures in adults over 16 years of age. Spritam can also be used for adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents (ages 12-16) with Juvenile Myoclonic Epilepsy (JME). Dosage: The dosage of Spritam depends on many factors like age, weight, medical history, and the severity of the condition. The recommended initial dose of Spritam is 500 mg twice a day for adults and children aged 16 years or older. The dosage can be increased by 1000 mg every 2 weeks, until the ideal response is achieved. The recommended maximum dosage is 3000 mg per day. For adolescents (ages 12-16) with Juvenile Myoclonic Epilepsy (JME), the dosage is 500 mg twice daily up to a maximum of 2000 mg/day. Administration of Spritam is through the mouth and can be taken with or without food. Demographic: Spritam is generally suitable for adults and children aged 16 years or older who are diagnosed with epilepsy. It is not recommended for individuals who are hypersensitive to levetiracetam or any of its components. Pregnant and nursing mothers should consult their doctor before using Spritam. Spritam may interact with other medications or supplements an individual might be using; hence it is vital to consult a doctor before using. Side Effects: The most common side effect of Spritam is drowsiness. Other side effects include headaches, fatigue, dizziness, agitation, mood swings, hostility, anxiety, irritability, and suicidal thoughts. Changes in vision, tremors, muscle weakness, joint pain, gastrointestinal upset, and skin rash have also been reported with the use of Spritam. These effects may vary from person to person and seriousness may also depend on age, gender, health status, and other factors. Interactions: Spritam can interact with other medications an individual may be taking; thus, it is essential to report all other medications and supplements being used to the doctor. Spritam can alter the efficacy of hormonal contraceptives, increasing the likelihood of unplanned pregnancy. It can also interact with alcohol, increasing central nervous system depressants' effects and causing extreme drowsiness. Generic Options: Levetiracetam is the generic name of Spritam and is available as a tablet, an oral solution, and an IV injection. There are several other generic medications available with the same active ingredient – Levetiracetam. The most commonly available ones are Keppra, Keppra XR, and Elepsia XR, and they are available in different forms and strengths. It is worth mentioning that although the generic options contain the same active ingredient as Spritam, their formulation may be different. Conclusion: Spritam (Levetiracetam) is a medication used to control seizures in people with epilepsy. It is available in the form of high-tech, 3D-printed tablets designed to dissolve in the mouth, which makes it easier to swallow for those who have difficulty swallowing tablets. It is recommended to be used under medical supervision and through the correct dosage. Spritam offers a new and innovative option for people with epilepsy, and there are several generic options available in other forms and strengths, allowing patients to choose according to their specific needs and preferences.